Eloxx Pharmaceuticals, Inc. (ELOX)
OTCMKTS · Delayed Price · Currency is USD
0.0500
-0.1250 (-71.43%)
At close: May 18, 2026
Eloxx Pharmaceuticals Employees
Eloxx Pharmaceuticals had 10 employees as of December 31, 2025. The number of employees decreased by 8 or -44.44% compared to the previous year.
Employees
10
Change (1Y)
-8
Growth (1Y)
-44.44%
Revenue / Employee
n/a
Profits / Employee
-$804,000
Market Cap
378.70K
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10 | -8 | -44.44% |
| Dec 31, 2022 | 18 | -10 | -35.71% |
| Dec 31, 2021 | 28 | 3 | 12.00% |
| Dec 31, 2020 | 25 | -4 | -13.79% |
| Dec 31, 2019 | 29 | 0 | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Orgenesis | 77 |
| Altamira Therapeutics | 11 |
| Actavia Life Sciences | 1 |
| Bio-Path Holdings | 1 |
| CNBX Pharmaceuticals | 1 |
Eloxx Pharmaceuticals News
- 2 years ago - Eloxx Pharmaceuticals Provides Pipeline and Financing Updates - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals provides ELX-02, ZKN-013 program updates - TheFly
- 2 years ago - Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals treatment of Alport Syndrome granted FDA orphan status - TheFly
- 2 years ago - Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases - GlobeNewsWire
- 2 years ago - Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases - Business Wire
- 2 years ago - Eloxx Pharmaceuticals files to sell 778,646 shares of common stock for holders - TheFly
- 2 years ago - Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update - GlobeNewsWire